A prognostic medicine product for prostate cancer.
Prostate Cancer
Approximately 241,000 men are diagnosed annually in the U.S. with prostate cancer. It is the most common cancer among U.S. males and is responsible for more deaths in men than any other cancer except lung cancer. Today the most common treatments for men diagnosed with localized prostate cancer include surgery, radiation and active surveillance.
PROLARIS
Optimal management of clinically localized prostate cancer presents a unique challenge to physicians and patients, because it is a highly variable and often slow growing, nonaggressive cancer. More men will die with prostate cancer than of it. Prolaris was developed to aid physicians in predicting disease aggressiveness in conjunction with clinical parameters such as Gleason score and PSA. Prolaris measures the expression level of genes involved with cell cycle progression to predict disease outcome. The signature has been evaluated in four retrospective clinical studies:
- A study of 366 patients which predicted biochemical recurrence in patients who had undergone radical prostatectomy
- A study of 413 patients which predicted biochemical recurrence in patients who had undergone radical prostatectomy
- A study of 337 patients which predicted ten year mortality risk in patients with clinically localized prostate cancer diagnosed by transurethral resection and managed conservatively (watchful waiting)
- A study of 352 patients which predicted ten year mortality risk in patients with clinically localized prostate cancer diagnosed by needle biopsy and managed conservatively (watchful waiting)
Prolaris was a statistically significant predictor of clinical outcomes in all four studies. Prolaris provides unique additional information about a patient’s prognosis and may be used with other clinical factors in helping the healthcare provider make treatment recommendations.
Please visit MyriadPro for more information.